{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T04:04:45Z","timestamp":1782014685428,"version":"3.54.5"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s12028-022-01521-3","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T17:02:57Z","timestamp":1653670977000},"page":"471-478","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of Factor Xa Inhibitor Reversal with Prothrombin Complex Concentrate in Patients with Traumatic Brain Injuries"],"prefix":"10.1007","volume":"37","author":[{"given":"Grace E.","family":"Cooksey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie A.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"McMillen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared H.","family":"Griffard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2533-9233","authenticated-orcid":false,"given":"A. Shaun","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,27]]},"reference":[{"key":"1521_CR1","unstructured":"Centers for Disease Control and Prevention. Surveillance Report of Traumatic Brain Injury-related Emergency Department Visits, Hospitalizations, and Deaths\u2014United States, 2014: Centers for Disease Control and Prevention, U.S. Department of Health and Human Services; 2019. https:\/\/www.cdc.gov\/traumaticbraininjury\/pdf\/TBI-Surveillance-Report-FINAL_508.pdf."},{"key":"1521_CR2","unstructured":"Scotti P, Seguin C, Lo BWY, de Guise E, Troquet JM, Marcoux J. Antithrombotic agents and traumatic brain injury in the elderly population: hemorrhage patterns and outcomes. J Neurosurg 2019:1\u201310."},{"issue":"9","key":"1521_CR3","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1177\/0885066618800657","volume":"35","author":"TA Allison","year":"2020","unstructured":"Allison TA, Lin PJ, Gass JA, et al. Evaluation of the use of low-dose 4-factor prothrombin complex concentrate in the reversal of direct oral anticoagulants in bleeding patients. J Intensive Care Med. 2020;35(9):903\u20138.","journal-title":"J Intensive Care Med"},{"issue":"2","key":"1521_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11739-018-1977-9","volume":"14","author":"M Sheikh-Taha","year":"2019","unstructured":"Sheikh-Taha M. Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate. Intern Emerg Med. 2019;14(2):265\u20139.","journal-title":"Intern Emerg Med"},{"key":"1521_CR5","doi-asserted-by":"crossref","unstructured":"Panos NG, Cook AM, John S, Jones GM, Neurocritical Care Society Pharmacy Study. Factor Xa inhibitor-related intracranial hemorrhage: results from a multicenter, observational cohort receiving prothrombin complex concentrates. Circulation 2020;141(21):1681\u20139.","DOI":"10.1161\/CIRCULATIONAHA.120.045769"},{"issue":"1","key":"1521_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11239-020-02154-z","volume":"51","author":"R Castillo","year":"2021","unstructured":"Castillo R, Chan A, Atallah S, et al. Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products. J Thromb Thrombolysis. 2021;51(1):151\u20138.","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"1521_CR7","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ajem.2018.05.023","volume":"37","author":"JM Engelbart","year":"2019","unstructured":"Engelbart JM, Zepeski A, Galet C, Policeni B, Skeete DA, Faine BA. Safety and effectiveness of Factor Eight Inhibitor Bypassing Activity for direct oral anticoagulant-related hemorrhage reversal. Am J Emerg Med. 2019;37(2):214\u20139.","journal-title":"Am J Emerg Med"},{"issue":"3","key":"1521_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40256-019-00383-z","volume":"20","author":"M Sheikh-Taha","year":"2020","unstructured":"Sheikh-Taha M, Crawley RM. Reversal of apixaban and rivaroxaban using activated prothrombin complex concentrates in patients with major bleeding. Am J Cardiovasc Drugs. 2020;20(3):295\u20139.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"1521_CR9","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12028-015-0222-x","volume":"24","author":"JA Frontera","year":"2016","unstructured":"Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the neurocritical care society and society of critical care medicine. Neurocrit care. 2016;24(1):6\u201346.","journal-title":"Neurocrit care"},{"key":"1521_CR10","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95:103208.","journal-title":"J Biomed Inform"},{"issue":"2","key":"1521_CR11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"issue":"5","key":"1521_CR12","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","volume":"76","author":"GF Tomaselli","year":"2020","unstructured":"Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution set oversight committee. J Am Coll Cardiol. 2020;76(5):594\u2013622.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"1521_CR13","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.ajem.2019.01.008","volume":"37","author":"D Dybdahl","year":"2019","unstructured":"Dybdahl D, Walliser G, Chance Spalding M, Pershing M, Kincaid M. Four-factor prothrombin complex concentrate for the reversal of factor Xa inhibitors for traumatic intracranial hemorrhage. Am J Emerg Med. 2019;37(10):1907\u201311.","journal-title":"Am J Emerg Med"}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-022-01521-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12028-022-01521-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-022-01521-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T14:29:42Z","timestamp":1664375382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12028-022-01521-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,27]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1521"],"URL":"https:\/\/doi.org\/10.1007\/s12028-022-01521-3","relation":{},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"value":"1541-6933","type":"print"},{"value":"1556-0961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,27]]},"assertion":[{"value":"23 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Author JCM is currently employed by Amgen. At the time of study development and conduct, JCM was not affiliated with Amgen. Amgen does not have a role in this project.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This project is institutional review board approved and complies with ethical guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval\/informed consent"}}]}}